Who are DAPT strategy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): extended postimplantation dual antiplatelet therapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dapt-strategy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

DAPT strategy — Competitive Intelligence Brief

DAPT strategy (DAPT strategy) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiplatelet therapy combination. Area: Cardiovascular.

phase 3 Antiplatelet therapy combination P2Y12 receptor and cyclooxygenase (COX) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

DAPT strategy (DAPT strategy) — Assistance Publique - Hôpitaux de Paris. DAPT (Dual Antiplatelet Therapy) strategy involves the concurrent use of two antiplatelet agents to prevent thrombotic events in cardiovascular disease.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
DAPT strategy TARGET	DAPT strategy	Assistance Publique - Hôpitaux de Paris	phase 3	Antiplatelet therapy combination	P2Y12 receptor and cyclooxygenase (COX)
extended postimplantation dual antiplatelet therapy	extended postimplantation dual antiplatelet therapy	National Institute of Cardiology, Warsaw, Poland	marketed	Antiplatelet therapy combination	Platelet aggregation pathways (cyclooxygenase and P2Y12 receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiplatelet therapy combination class)

Assistance Publique - Hôpitaux de Paris · 1 drug in this class
National Institute of Cardiology, Warsaw, Poland · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DAPT strategy — Competitive Intelligence Brief. https://druglandscape.com/ci/dapt-strategy. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab